Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity.

Area of Science:

• Neuroscience
• Immunology
• Alzheimer's Disease Research

Background:

• Genetic evidence links microglia and the complement system in Alzheimer's Disease (AD).
• The role of microglial complement receptor 3 (CR3) in amyloid-beta (Aβ) regulation is not fully understood.

Purpose of the Study:

• To investigate the novel role of microglial CR3 in soluble Aβ clearance.
• To explore CR3's impact on Aβ accumulation and degradation in AD models.

Main Methods:

• Utilized human amyloid precursor protein-transgenic mouse models with CR3 ablation.
• Examined Aβ levels in cultured microglia and in vivo using microdialysis.
• Analyzed extracellular Aβ degradation by microglia.

Main Results:

• CR3 ablation in mice led to decreased, not increased, Aβ accumulation.
• CR3-deficient microglia showed enhanced extracellular Aβ degradation via secreted enzymes like tissue plasminogen activator.
• A CR3 modulator reduced soluble Aβ levels and half-life in brain interstitial fluid.

Conclusions:

• Microglial CR3 limits soluble Aβ clearance from brain interstitial fluid, contrary to expectations.
• CR3 plays a novel role in brain Aβ metabolism.
• CR3 represents a potential therapeutic target for Alzheimer's Disease.